- Efficacy of Finerenone in Primary Cardiovascular Prevention: A Mechanistic Analysis Using the AHA PREVENT™ Risk Score
-
MDP0825
Ashish Verma, Dept of Med, Section of Nephrology, Boston Medical Ctr, and Boston Univ Chobanian & Avedisian Sch of Med, Boston, MA; Rajiv Agarwal, Indiana Univ Sch of Med and Richard L. Roudebush VA Medical Ctr, Indianapolis, IN; Stefan D Anker, Dept of Cardiology (CVK) of German Heart Ctr Charité; German Ctr for Cardiovascular Res (DZHK) partner site Berlin, Charité Univsmedizin, Berlin, Germany; Sophie E Claudel, Dept of Med, Section of Nephrology, Boston Medical Ctr, and Boston Univ Chobanian & Avedisian Sch of Med, Boston, MA; Bertram Pitt, Dept of Med, Univ of Michigan Sch of Med, Ann Arbor, MI; Peter Rossing, Steno Diabetes Ctr Copenhagen, Copenhagen, Denmark; Luis M Ruilope, Cardiorenal Translational Lab and Hypertension Unit, Inst of Res imas12, Madrid, Spain; Anand Vaidya, Div of Endocrinology, Diabetes, and Metabolism, Mass General Brigham and Harvard Medical Sch, Boston, MA; Sushrut Waikar, Insa M Schmidt, Dept of Med, Section of Nephrology, Boston Medical Ctr, and Boston Univ Chobanian & Avedisian Sch of Med, Boston, MA; Sonia Gomez, Syneos Health LLC (providing service to Bayer), Morrisville, NC; Margarida Seco, Global Medical Affairs Cardiorenal, Bayer Portugal SA, Lisbon, Portugal; Zihe Zheng, Medical Affairs Cardio-Renal Div, Bayer U.S. LLC, Whippany, NJ; Gerasimos Filippatos, Natl and Kapodistrian Univ of Athens, Sch of Med, Dept of Cardiology, Attikon Univ Hosp, Athens, GreeceGeneric 'disconnected' MessageCommunitiesNavigationSession TypeOnsite Viewing
Enter Note
Go to previous page in this tab
Session


